榮昌生物(09995.HK)向Vor Bio授出泰它西普大中華外獨家開發權
榮昌生物(09995.HK)公布,將具有自主知識產權的泰它西普有償許可給Vor Bio(VOR.US),Vor Bio將獲得在除大中華區(即中國、香港、澳門及台灣)以外的全球範圍內開發和商業化的獨家權利,以及Vor Bio將向公司全資持有榮普合夥發行認股權證,作為公司向Vor Bio授予許可協議項下權利的部分對價。
據此,Vor Bio應向榮昌生物及榮普合夥支付總價值1.25億美元的代價,其中包括公司將從Vor Bio取得4,500萬美元的首付款和Vor Bio將向榮普合夥發行價值8,000萬美元的認股權證,持有人可認購Vor Bio 3.2億股的普通股,約佔Vor Bio經擴大總發行股本的23%;基於臨床開發進度及上市後的銷售情況,Vor Bio應向公司支付最高達41.05億美元的數個潛在適應症的里程碑付款;Vor Bio將向公司支付達到實際年淨銷售額高個位數至雙位數比例的銷售提成。
泰它西普是全球首個由公司自主研發的重組B淋巴細胞刺激因數(BLyS)/增殖誘導配體(APRIL)雙靶點融合蛋白,通過同時抑制BLyS和APRIL與B細胞表面受體結合,阻斷B細胞異常分化和成熟。目前在中國已獲批治療重症肌無力(MG)、系統性紅斑狼瘡(SLE)和類風濕關節炎(RA)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.